These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36940443)

  • 1. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
    Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG
    Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
    Sarayani A; Hampp C; Brown JD; Donahoo WT; Winterstein AG
    Drug Saf; 2022 Dec; 45(12):1517-1527. PubMed ID: 36318419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
    Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
    Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
    [No Abstract]   [Full Text] [Related]  

  • 7. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
    Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
    Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medications for Obesity: A Review.
    Gudzune KA; Kushner RF
    JAMA; 2024 Aug; 332(7):571-584. PubMed ID: 39037780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
    Levin A; Kaur N; Mainoo NK; Perez A
    Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S; Schwartz LM
    JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
    Mital S; Nguyen HV
    JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
    Lim F; Bellows BK; Tan SX; Aziz Z; Woo Baidal JA; Kelly AS; Hur C
    JAMA Netw Open; 2023 Aug; 6(8):e2329178. PubMed ID: 37651143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of newer anti-obesity medications in a real-world setting.
    Ganguly R; Tian Y; Kong SX; Hersloev M; Hobbs T; Smolarz BG; Ramasamy A; Haase CL; Weng W
    Diabetes Res Clin Pract; 2018 Sep; 143():348-356. PubMed ID: 30009937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
    Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety During and After Use of Phentermine and Topiramate.
    Ritchey ME; Harding A; Hunter S; Peterson C; Sager PT; Kowey PR; Nguyen L; Thomas S; Cainzos-Achirica M; Rothman KJ; Andrews EB; Anthony MS
    J Clin Endocrinol Metab; 2019 Feb; 104(2):513-522. PubMed ID: 30247575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
    Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
    Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.